VERU INC (VERU) Stock Price, Forecast & Analysis
NASDAQ:VERU • US92536C2026
VERU Key Statistics, Chart & Performance
The current stock price of VERU is 2.29 USD. In the past month the price decreased by -5.37%. In the past year, price decreased by -57.69%.
VERU Technical Analysis
VERU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VERU. The financial health of VERU is average, but there are quite some concerns on its profitability.
VERU Financial Highlights
Over the last trailing twelve months VERU reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 55.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.17% | ||
| ROE | -123.97% | ||
| Debt/Equity | 0 |
VERU Forecast & Estimates
8 analysts have analysed VERU and the average price target is 25.5 USD. This implies a price increase of 1013.54% is expected in the next year compared to the current price of 2.29.
VERU Ownership
VERU Latest News, Press Relases and Analysis
VERU Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VERU
Company Profile
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. The company is headquartered in Miami, Florida and currently employs 20 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Company Info
VERU INC
2916 N. Miami Avenue, Suite 1000
Miami FLORIDA 33127 US
CEO: Mitchell S. Steiner
Employees: 20
Phone: 13125959123
VERU INC / VERU FAQ
Can you describe the business of VERU INC?
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. The company is headquartered in Miami, Florida and currently employs 20 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Can you provide the latest stock price for VERU INC?
The current stock price of VERU is 2.29 USD. The price increased by 2.23% in the last trading session.
Does VERU stock pay dividends?
VERU does not pay a dividend.
How is the ChartMill rating for VERU INC?
VERU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for VERU INC?
VERU INC (VERU) operates in the Health Care sector and the Pharmaceuticals industry.
Is VERU INC (VERU) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VERU.
What is the Short Interest ratio of VERU INC (VERU) stock?
The outstanding short interest for VERU INC (VERU) is 5.62% of its float.